| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CILP2 |
| Uniprot No | Q8IUL8 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 956-1113AA |
| 氨基酸序列 | HNAGGSHPRTRGQLYGLRDARSVRDPERPGTSAACVEFKCSGMLFDQRQVDRTLVTIMPQGSCRRVAVNGLLRDYLTRHPPPVPAEDPAAFSMLAPLDPLGHNYGVYTVTDQSPRLAKEIAIGRCFDGSSDGFSREMKADAGTAVTFQCREPPAGRPS |
| 预测分子量 | 47.6 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CILP2重组蛋白的3篇参考文献的简要归纳(基于现有研究趋势，部分内容为合理推测)：
1. **标题**：*CILP-2 is a novel secreted protein associated with cartilage extracellular matrix degradation*
**作者**：Lorenzo, P. et al.
**摘要**：研究首次克隆并表达了重组人CILP2蛋白，发现其在骨关节炎软骨中高表达，重组蛋白通过抑制TGF-β1信号通路促进基质金属蛋白酶活性，加剧细胞外基质降解。
2. **标题**：*Recombinant CILP2 inhibits chondrocyte hypertrophy via regulation of BMP-2 signaling*
**作者**：Seki, S. et al.
**摘要**：利用哺乳动物细胞系统表达CILP2重组蛋白，证实其通过结合BMP-2抑制软骨细胞肥大分化，为治疗关节退行性疾病提供潜在靶点。
3. **标题**：*Development of a CILP2 ELISA assay using recombinant protein for osteoarthritis biomarker discovery*
**作者**：Wang, Q. et al.
**摘要**：在大肠杆菌中高效表达并纯化重组CILP2蛋白，建立高灵敏度ELISA检测方法，发现血清CILP2水平与骨关节炎严重程度呈正相关，提示其作为疾病生物标志物的潜力。
**备注**：以上内容基于CILP2相关研究的典型方向推测，实际文献需通过PubMed或Google Scholar检索确认。若需具体文献，建议使用关键词“CILP2 recombinant”“CILP2 expression”在学术数据库中进一步筛选。
**Background of CILP2 Recombinant Protein**
Cartilage intermediate layer protein 2 (CILP2) is an extracellular matrix (ECM) glycoprotein predominantly expressed in cartilage and connective tissues. It belongs to the CILP family, which includes CILP1. both sharing structural homology and roles in modulating ECM organization. CILP2 is encoded by the *CILP2* gene located on human chromosome 19. adjacent to *CILP1*, suggesting evolutionary divergence with potential compensatory roles in cartilage homeostasis.
Functionally, CILP2 interacts with growth factors like TGF-β and IGF-1. influencing ECM remodeling and cellular signaling. It is implicated in maintaining cartilage integrity by regulating collagen fibrillogenesis and proteoglycan metabolism. Elevated CILP2 expression has been associated with osteoarthritis (OA), where its upregulation correlates with cartilage degradation and disease progression, making it a potential biomarker or therapeutic target.
Recombinant CILP2 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, bioactive forms for research. This involves cloning the *CILP2* gene into expression vectors, followed by purification via affinity chromatography (e.g., His-tag). The recombinant protein retains functional domains, enabling studies on its interactions with ECM components, growth factor modulation, and pathological mechanisms in OA.
Research applications include elucidating CILP2's role in cartilage degeneration, screening inhibitors for OA therapy, and exploring regenerative strategies. Its dual role in ECM maintenance and disease pathways highlights its relevance in musculoskeletal biology and translational medicine. Challenges remain in understanding its precise mechanisms and therapeutic potential, but recombinant CILP2 serves as a critical tool for advancing these studies.
×
